Vermeire, S., Louis, E., Carbonez, A., Van Assche, G., Noman, M., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., & Rutgeerts, P. (September 2002). Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. American Journal of Gastroenterology, 97 (9), 2357-2363. doi:10.1111/j.1572-0241.2002.05991.x Peer Reviewed verified by ORBi |
Louis, E., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., D'Haens, G., Malaise, M., & Belaiche, J. (July 2002). A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scandinavian Journal of Gastroenterology, 37 (7), 818-824. doi:10.1080/713786515 Peer Reviewed verified by ORBi |
Vermeire, S., Louis, E., Rutgeerts, P., De Vos, M., Van Gossum, A., Belaiche, J., Pescatore, P., Fiasse, R., Pelckmans, P., Vlietinck, R., Merlin, F., Zouali, H., Thomas, G., Colombel, J. F., & Hugot, J. P. (July 2002). NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 123 (1), 106-111. doi:10.1053/gast.2002.34172 Peer Reviewed verified by ORBi |
Esters, N., Vermeire, S., Joossens, S., Noman, M., Louis, E., Belaiche, J., De Vos, M., Van Gossum, A., Pescatore, P., Fiasse, R., Pelckmans, P., Reynaert, H., Poulain, D., Bossuyt, X., & Rutgeerts, P. (June 2002). Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. American Journal of Gastroenterology, 97 (6), 1458-1462. doi:10.1111/j.1572-0241.2002.05689.x Peer Reviewed verified by ORBi |